Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Aug;33(8):1298–1301. doi: 10.1128/aac.33.8.1298

Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis.

L Heifets 1, P Lindholm-Levy 1
PMCID: PMC172643  PMID: 2478073

Abstract

The bactericidal activities of four injectable antituberculosis drugs, streptomycin, amikacin, kanamycin, and capreomycin, against Mycobacterium avium and M. tuberculosis were tested. All four drugs were highly bactericidal against M. tuberculosis, with low MBC/MIC ratios and MBCs significantly lower than the maximum achievalbe concentrations in serum (Cmax). In contrast, all four drugs had very low bactericidal activities against M. avium: the broth-determined MBCs were significantly higher than the Cmax. On a basis of comparisons with the broth-determined MICs found for susceptible M. tuberculosis strains and with the Cmax, about one-third of 100 M. avium strains tested can be tentatively considered as susceptible to three aminoglycosides (streptomycin, amikacin, and kanamycin) but not to capreomycin. In regard to the MBCs and MICs, the three aminoglycosides tested have about identical potentials as drugs of choice in combination with other drugs for chemotherapy of M. avium disease. The low bactericidal activities of these drugs against M. avium in vitro do not exclude their therapeutic usefulness, because they may produce a synergistic effect in combination with other drugs. Such an option is especially promising for patients whose isolates can be considered susceptible on the basis of the MIC. We found no differences in susceptibility to the four drugs tested for M. avium strains (identified by Gen-Probe) isolated from 50 patients with and 50 patients without acquired immune deficiency syndrome.

Full text

PDF
1298

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baron E. J., Young L. S. Amikacin, ethambutol, and rifampin for treatment of disseminated Mycobacterium avium-intracellulare infections in patients with acquired immune deficiency syndrome. Diagn Microbiol Infect Dis. 1986 Sep;5(3):215–220. doi: 10.1016/0732-8893(86)90004-0. [DOI] [PubMed] [Google Scholar]
  2. Davis C. E., Jr, Carpenter J. L., Trevino S., Koch J., Ognibene A. J. In vitro susceptibility of Mycobacterium avium complex to antibacterial agents. Diagn Microbiol Infect Dis. 1987 Nov;8(3):149–155. doi: 10.1016/0732-8893(87)90165-9. [DOI] [PubMed] [Google Scholar]
  3. Dickinson J. M., Aber V. R., Mitchison D. A. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis. Am Rev Respir Dis. 1977 Oct;116(4):627–635. doi: 10.1164/arrd.1977.116.4.627. [DOI] [PubMed] [Google Scholar]
  4. Düzgüneş N., Perumal V. K., Kesavalu L., Goldstein J. A., Debs R. J., Gangadharam P. R. Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice. Antimicrob Agents Chemother. 1988 Sep;32(9):1404–1411. doi: 10.1128/aac.32.9.1404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gangadharam P. R., Kesavalu L., Rao P. N., Perumal V. K., Iseman M. D. Activity of amikacin against Mycobacterium avium complex under simulated in vivo conditions. Antimicrob Agents Chemother. 1988 Jun;32(6):886–889. doi: 10.1128/aac.32.6.886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gangadharam P. R., Perumal V. K., Podapati N. R., Kesavalu L., Iseman M. D. In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice. Antimicrob Agents Chemother. 1988 Sep;32(9):1400–1403. doi: 10.1128/aac.32.9.1400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Heifets L. B., Iseman M. D., Lindholm-Levy P. J. Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects. Am Rev Respir Dis. 1988 Mar;137(3):711–715. doi: 10.1164/ajrccm/137.3.711. [DOI] [PubMed] [Google Scholar]
  8. Heifets L. B., Iseman M. D., Lindholm-Levy P. J. Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1986 Dec;30(6):927–932. doi: 10.1128/aac.30.6.927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Heifets L. B., Lindholm-Levy P. J. Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle. 1987 Dec;68(4):267–276. doi: 10.1016/0041-3879(87)90067-5. [DOI] [PubMed] [Google Scholar]
  10. Heifets L. B., Lindholm-Levy P. J., Iseman M. D. Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. Am Rev Respir Dis. 1988 Mar;137(3):719–721. doi: 10.1164/ajrccm/137.3.719. [DOI] [PubMed] [Google Scholar]
  11. Heifets L. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob Agents Chemother. 1988 Aug;32(8):1131–1136. doi: 10.1128/aac.32.8.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Heifets L. Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am Rev Respir Dis. 1988 May;137(5):1217–1222. doi: 10.1164/ajrccm/137.5.1217. [DOI] [PubMed] [Google Scholar]
  13. Holdiness M. R. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet. 1984 Nov-Dec;9(6):511–544. doi: 10.2165/00003088-198409060-00003. [DOI] [PubMed] [Google Scholar]
  14. Horsburgh C. R., Jr, Cohn D. L., Roberts R. B., Masur H., Miller R. A., Tsang A. Y., Iseman M. D. Mycobacterium avium-M. intracellulare isolates from patients with or without acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1986 Dec;30(6):955–957. doi: 10.1128/aac.30.6.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Inderlied C. B., Kolonoski P. T., Wu M., Young L. S. Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige mice. Antimicrob Agents Chemother. 1989 Feb;33(2):176–180. doi: 10.1128/aac.33.2.176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Inderlied C. B., Young L. S., Yamada J. K. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob Agents Chemother. 1987 Nov;31(11):1697–1702. doi: 10.1128/aac.31.11.1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Naito Y., Kuze F., Maekawa N. [Sensitivities of atypical mycobacteria to various drugs. V. Sensitivities of Mycobacterium intracellulare to some aminoglycoside and peptide antibiotics (author's transl)]. Kekkaku. 1979 Aug;54(8):423–427. [PubMed] [Google Scholar]
  18. Nozawa R. T., Kato H., Yokota T. Intra- and extracellular susceptibility of Mycobacterium avium-intracellulare complex to aminoglycoside antibiotics. Antimicrob Agents Chemother. 1984 Dec;26(6):841–844. doi: 10.1128/aac.26.6.841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pearson R. D., Steigbigel R. T., Davis H. T., Chapman S. W. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother. 1980 Nov;18(5):699–708. doi: 10.1128/aac.18.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sanders W. E., Jr, Hartwig C., Schneider N., Cacciatore R., Valdez H. Activity of amikacin against Mycobacteria in vitro and in murine tuberculosis. Tubercle. 1982 Sep;63(3):201–208. doi: 10.1016/s0041-3879(82)80031-7. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES